ArQule Message Board - Msg: 10597249

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule

ARQL 20.00

0.0%

Jan 16 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: noronha who wrote ()	7/21/1999 12:51:00 PM
From: Rigorous	of 399

biz.yahoo.com Wednesday July 21, 10:30 am Eastern Time Arqule , Pfizer in $117 mln deal MEDFORD, Mass., July 21 (Reuters) - ArQule Inc. said Wednesday that it has signed a multi-year drug research and technology licensing partnership with Pfizer Inc. worth up to $117 million over four and a half years. Arqule also reported a second quarter loss of $0.29 a share on total revenues of $4.6 million, compared to a loss of $0.05 a share on revenues of $6.0 million the previous second quarter. The company said it will devote designated technologies, scientists, and its AMAP Chemistry Operating System at its Medford, Massachusetts facility to generate compound libraries for Pfizer. The AMAP system is a highly automated and integrated series of chemistry workstations that rapidly generate thousands of novel, pure, single drug-like molecules for drug discovery.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next